Comparative Pharmacology
Head-to-head clinical analysis: AXID versus RANICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID versus RANICLOR.
AXID vs RANICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive, reversible inhibition of histamine at H2-receptors on gastric parietal cells, reducing gastric acid secretion by blocking the H2-receptor-mediated activation of adenylate cyclase and subsequent cAMP production.
Ranitidine is a histamine H2-receptor antagonist that competitively inhibits the action of histamine on parietal cells, thereby reducing gastric acid secretion.
300 mg orally once daily at bedtime or 150 mg orally twice daily. Max 300 mg/day.
12.5 mg orally twice daily, increased to 25 mg twice daily after 2 weeks if tolerated; maximum 50 mg twice daily.
None Documented
None Documented
1.5-2.5 hours (prolonged in renal impairment: up to 4-5 hours if CrCl <20 mL/min)
Terminal elimination half-life: 8-12 hours (mean 10 hours) in healthy adults; prolonged in renal impairment (up to 20 hours) and elderly.
Renal (60% unchanged), biliary (30%), fecal (<10%)
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist